Pier 88 Investment Partners’s CRISPR Therapeutics CRSP Stock Holding History

Pier 88 Investment Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,600	Closed	-$197K	–	88
2021 Q4	$197K	Sell	2,600 -4,865	-65%	-$425K	0.04%	102
2021 Q3	$835K	Buy	7,465 +370	+5%	+$46.5K	0.25%	77
2021 Q2	$1.15M	Buy	7,095 +4,300	+154%	+$523K	0.33%	72
2021 Q1	$341K	Hold	2,795	–	–	0.12%	102
2020 Q4	$428K	Sell	2,795 -5,500	-66%	-$650K	0.14%	101
2020 Q3	$694K	Sell	8,295 -12,352	-60%	-$1.1M	0.21%	83
2020 Q2	$1.52M	Buy	20,647 +10,317	+100%	+$603K	0.43%	60
2020 Q1	$438K	Buy	10,330 +8,790	+571%	+$454K	0.16%	81
2019 Q4	$94K	Buy	+1,540	New	+$84.1K	0.04%	94

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pier 88 Investment Partners's CRSP Position: Q1 2022 in Review

Pier 88 Investment Partners sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 2,600 shares — an estimated $197K sold.

Pier 88 Investment Partners first reported a position in CRSP in Q4 2019 and held it in 9 quarters. The position peaked at $1.52M in Q2 2020. 447 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

Pier 88 Investment Partners reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
Pier 88 Investment Partners sold 2,600 CRISPR Therapeutics shares in Q1 2022, an estimated $197K.
Pier 88 Investment Partners first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 9 quarters.
Pier 88 Investment Partners's CRISPR Therapeutics position peaked at $1.52M in Q2 2020.
447 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Pier 88 Investment Partners's 13F filing for Q1 2022, filed 13 May 2022.